🌍 It’s #WorldTBDay, and we need a new vaccine for the world’s deadliest infectious disease. Tuberculosis (TB) caused 1.25 million deaths in 2023 despite existing treatment options. A safe and effective vaccine would be a powerful tool to drive down #TB infections, morbidity, and deaths in high-burden countries and communities. Currently, there is only one licensed vaccine for TB: BCG, which was developed over 100 years ago and is only effective in children. It offers limited protection for adolescents and adults. The need for a new vaccine to augment the narrow protection offered by BCG is urgent. That’s why we were so excited to announce the kickoff of IAVI’s large-scale efficacy trial for MTBVAC, one of the most promising TB vaccine candidates in development today. ▶️ Learn more about MTBVAC and the IMAGINE clinical trial! Watch this video with commentary from IAVI staff. Biofabri | ZENDAL | Universidad de Zaragoza #EndTB #VaccinesWork
